Beta Bionics (BBNX) Cost of Revenue (2024 - 2026)

Beta Bionics has disclosed Cost of Revenue across 3 years of filings, most recently posting $20.7 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $20.7 million, up 139.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.7 million (up 71.12% YoY), and the FY2025 annual result was $44.7 million, up 52.94% from the prior year.
• Cost of Revenue came in at $20.7 million for Q1 2026 at Beta Bionics, up from $13.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $20.7 million in Q1 2026 to a low of $5.7 million in Q1 2024.
• The 3-year median for Cost of Revenue is $9.6 million (2024), against an average of $11.5 million.
• Across the five-year window, Cost of Revenue gained 25.81% in 2025 and soared 139.21% in 2026, its largest moves.
• Beta Bionics' Cost of Revenue stood at $8.8 million in 2024, then surged by 50.58% to $13.2 million in 2025, then jumped by 57.36% to $20.7 million in 2026.
• The last three Cost of Revenue figures came in at $20.7 million (Q1 2026), $13.2 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.